title: Arginine vasopressin enhances sympathetic constriction through the V1 vasopressin receptor in human saphenous vein.
abstract: BACKGROUND
  Arginine vasopressin (AVP) not only acts directly on blood vessels through V1 receptor stimulation but also may modulate adrenergic-mediated responses in animal experiments in vivo and in vitro. The aim of the present study was to investigate whether AVP can contribute to an abnormal adrenergic constrictor response of human saphenous veins.
  
  
  RESULTS
  Saphenous vein rings were obtained from 32 patients undergoing coronary artery bypass surgery. The vein rings were suspended in organ bath chambers for isometric recording of tension. AVP (3x10[-9] mol/L) enhanced the contractions elicited by electrical field stimulation at 1, 2, and 4 Hz (by 80%, 70%, and 60%, respectively) and produced a leftward shift of the concentration-response curve to norepinephrine (half-maximal effective concentration decreased from 6.87x10[-7] to 1.04x10[-7] mol/L; P<.05). The V1 vasopressin receptor antagonist d(CH2)5Tyr(Me)AVP (10[-6] mol/L) prevented the potentiation evoked by AVP. The selective V1 receptor agonist [Phe,2 Orn8]-vasotocin (3x[-10]-9 mol/L) induced potentiation of electrical stimulation-evoked responses, which was also inhibited in the presence of the V1 receptor antagonist (10[-6] mol/L). In contrast, the V2 receptor agonist desmopressin (10[-9] to 10[-7] mol/L) did not modify neurogenic responses, and the V2 receptor antagonist [d(CH2)5, D-Ile,2 Ile,4 Arg8]-vasopressin (10[-8] to 10[-6] mol/L) did not prevent the potentiation induced by AVP. The dihydropyridine calcium antagonist nifedipine (10[-6] mol/L) did not affect the potentiating effect of AVP.
  
  
  CONCLUSIONS
  The results suggest that low concentrations of AVP facilitate sympathetic neurotransmission and potentiate constrictor effects of norepinephrine in human saphenous veins. These effects appear to be mediated by V1 receptor stimulation and are independent of calcium entry through dihydropyridine calcium channels. Thus, AVP may contribute to vascular mechanisms involved in acute ischemic syndromes associated with venous grafts, particularly if the sympathetic nervous system is activated.
authors.affiliation: Department of Physiology, University of Valencia, Spain.
authors.forename: P
authors.initials: P
authors.lastname: Medina
authors.forename: A
authors.initials: A
authors.lastname: Acuña
authors.forename: J B
authors.initials: JB
authors.lastname: Martínez-León
authors.forename: E
authors.initials: E
authors.lastname: Otero
authors.forename: J M
authors.initials: JM
authors.lastname: Vila
authors.forename: M
authors.initials: M
authors.lastname: Aldasoro
authors.forename: S
authors.initials: S
authors.lastname: Lluch
mesh_terms: D000368:Aged; D065092:Antidiuretic Hormone Receptor Antagonists; D001127:Arginine Vasopressin / Q000502:physiology*; D002121:Calcium Channel Blockers / Q000494:pharmacology; D046508:Culture Techniques; D004558:Electric Stimulation; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D009543:Nifedipine / Q000494:pharmacology; D009638:Norepinephrine / Q000494:pharmacology; D011189:Potassium Chloride / Q000494:pharmacology; D017483:Receptors, Vasopressin / Q000187:drug effects / Q000502:physiology*; D012501:Saphenous Vein / Q000502:physiology*
chemical_list: D065092:Antidiuretic Hormone Receptor Antagonists; D002121:Calcium Channel Blockers; D017483:Receptors, Vasopressin; D001127:Arginine Vasopressin; D011189:Potassium Chloride; D009543:Nifedipine; D009638:Norepinephrine